Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 2, 2008, Pages

  Huang, Shang Yu ^a   Chueh, Ho Yen ^a   Shaw, Sheng Wen ^a   Shih, Jin Chung ^b   Cheng, Po Jen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

bifid nose; micrognathia; microtia; mycophenolate mofetil; three dimensional ultrasound

Indexed keywords

CYCLOPHOSPHAMIDE; FELODIPINE; HYDROXYCHLOROQUINE; IRBESARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AMNIOCENTESIS; ANAMNESIS; ARTICLE; CASE REPORT; CHORION VILLUS SAMPLING; DRUG SUBSTITUTION; EMBRYOPATHY; FACE MALFORMATION; FACE PROFILE; FEMALE; FETUS ECHOGRAPHY; FETUS GROWTH; FETUS MALFORMATION; FETUS MONITORING; GENETIC ANALYSIS; GENETIC COUNSELING; HETEROZYGOTE; HUMAN; HYDRAMNIOS; HYPERTELORISM; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MICROGNATHIA; MICROTIA; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THREE DIMENSIONAL IMAGING;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ADULT; EAR, EXTERNAL; FACIES; FEMALE; FETUS; HUMANS; IMAGING, THREE-DIMENSIONAL; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; NOSE; PREGNANCY; PREGNANCY COMPLICATIONS; ULTRASONOGRAPHY, PRENATAL;

EID: 48149085299     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.008     Document Type: Article

References (11)

1. Sollinger H.W., and US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225-232
2. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
3. Pirsch J.D., and Sollinger H.W. Mycophenolate mofetil-clinical and experimental experience. Ther Drug Monit 18 (1996) 357-361
4. Tendron A., Gouyon J.B., and Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 17 (2002) 121-130
5. Sifontis N.M., Coscia L.A., Constantinescu S., Lavelanet A.F., Moritz M.J., and Armenti V.T. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82 (2006) 1698-1702
6. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 (2004) 1091-1094
7. Perez-Aytes A., Ledo A., Boso V., et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype?. Am J Med Genet A 146 (2008) 1-7
8. El Sebaaly Z., Charpentier B., and Snanoudj R. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22 (2007) 2722
9. Velinov M., and Zellers N. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol 17 (2008) 77-78
10. Schoner K., Steinhard J., Figiel J., and Rehder H. Severe facial clefts in acrofacial dysostosis: A consequence of prenatal exposure to mycophenolate mofetil?. Obstet Gynecol 111 (2008) 483-486
11. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 7 Suppl (2002) 50-55